RVL Completes Financial Restructuring
November 27, 2023 06:50 ET
|
RVL Pharmaceuticals plc
Athyrium Provides Capital to Support Long-Term Growth and Exchanges Outstanding Debt into Equity of Certain Reorganized Entities RVL Pharmaceuticals plc Ordinary Shares Expected to be Cancelled in...
RVL Pharmaceuticals plc Announces Prepackaged Reorganization of Certain U.S. Subsidiaries
October 12, 2023 06:50 ET
|
RVL Pharmaceuticals plc
Lender to Provide Incremental Liquidity to Support Long-Term Growth Senior Secured Lender to Exchange Outstanding Debt into Equity of the Reorganized Entities Business Operations at U.S....
RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 23, 2023 16:05 ET
|
RVL Pharmaceuticals plc
BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief...
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
August 16, 2023 08:00 ET
|
RVL Pharmaceuticals plc
BRIDGEWATER, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ®...
RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business Review
August 14, 2023 06:50 ET
|
RVL Pharmaceuticals plc
-- UPNEEQ® remains a significant potential value driver given its rapid early acceptance by providers, large total addressable market and untapped consumer opportunity -- -- Executed financing...
RVL Pharmaceuticals plc to Discuss Second Quarter 2023 Financial Results and Provide Commercial Update
August 02, 2023 08:30 ET
|
RVL Pharmaceuticals plc
BRIDGEWATER, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ®...
RVL Pharmaceuticals plc Provides Business Update
July 05, 2023 06:50 ET
|
RVL Pharmaceuticals plc
BRIDGEWATER, N.J., July 05, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company organized in Ireland focused on the...
RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting
June 15, 2023 16:15 ET
|
RVL Pharmaceuticals plc
BRIDGEWATER, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced results of the proposal to...
RVL Pharmaceuticals plc Reports First Quarter 2023 Financial Results; Provides Commercial Update
May 11, 2023 06:50 ET
|
RVL Pharmaceuticals plc
-- First quarter 2023 UPNEEQ® net product sales grew 49%, or $2.9 million, over the prior year period to $8.8 million -- -- Enhanced operating leverage with a 32%, or $7.9 million, reduction in...
RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update
May 04, 2023 06:50 ET
|
RVL Pharmaceuticals plc
BRIDGEWATER, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ®...